Department of Physiology, Harold Hamm Diabetes Center, The University of Oklahoma Health Science Center, Oklahoma City, United States ...

Dose-response demonstrated for a range of 5 to 80 mg/kg/day achieving up to 38% weight loss in DIO mice Semaglutide treatment followed by its replacement with CRB-913 demonstrated continued weight ...

Two obesity proof-of-concept studies with IC 100 in diet-induced obesity (DIO) mouse models are planned, which will include ...

The research study tested a murine equivalent of SRK-439 in a diet-induced obesity, or DIO, mouse model. All mice were given a high-fat diet, followed by either metformin or control for four weeks.

To investigate the response of reproductive tissues to hyperinsulinemia, we used a mouse model of infertility associated with DIO. Hence, it is likely that a hormonal milieu that differs between ...

This study uncovers the hepatic vagal nerve's influence on circadian food intake, presenting new avenues for obesity treatment through targeted interventions.

Scholar Rock (SRRK) announced new preclinical data that support the potential of SRK-439, a highly selective investigational antimyostatin ...

CRB-913 demonstrated a wide dose response weight loss curve in DIO mice ranging from 5 mg/kg/day to 80 mg/kg/day with no plateauing effect and reaching a weight loss of 31% by day 19. Extending the ...

CRB-913 brain levels are 15-fold lower than monlunabant in lean mice Dose-response demonstrated for a range of 5 to 80 mg/kg/day achieving up to 38% weight loss in DIO mice Semaglutide treatment ...